GGrantIndex
← Leaderboards

University Of Calif-Lawrnc Lvrmr Nat Lab

Livermore, CA

Compare ↔
$80,901,702
Total funding
253
Grants

Funding over time

peak $10.8M · FY2005–21
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$80,901,702 · 253

By mechanism

P41$32,899,066 · 197
R01$30,189,520 · 21
U19$6,366,809 · 6
R21$4,506,962 · 8
U01$2,992,464 · 1
P01$2,655,366 · 17

Investigators at University Of Calif-Lawrnc Lvrmr Nat Lab

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

1Alan Daniel McCartt$2,977,3951 gr2Aleksandr Noy$1,162,5761 gr3Vadim A Frolov$1,162,5761 gr

All-Time

Most funded here, all years

1Krzysztof A Fidelis$11,157,1562 gr2Lisa Stubbs$5,792,0734 gr3Lawrence H Thompson$4,194,1503 gr4Joomyeong Kim$4,179,1933 gr5Alan Daniel McCartt$2,977,3951 gr6Gabriela G Loots$2,970,6373 gr7Pejman Naraghi-Arani$2,241,9021 gr8Chong-Xian Pan$1,782,9121 gr

Largest grants

Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)$2,998,785
P41 · FY2011 · RR
CARCINOGENIC SIGNIFICANCE OF HETERCYCLIC AMINES$2,572,557
P01 · FY2005 · CA
CARCINOGENIC SIGNIFICANCE OF HETERCYCLIC AMINES$2,565,593
P01 · FY2004 · CA
CARCINOGENIC SIGNIFICANCE OF HETERCYCLIC AMINES$2,548,940
P01 · FY2006 · CA
CARCINOGENIC SIGNIFICANCE OF HETERCYCLIC AMINES$2,524,887
P01 · FY2003 · CA
CARCINOGENIC SIGNIFICANCE OF HETERCYCLIC AMINES$2,419,052
P01 · FY2002 · CA
Center for Biologically Inspired Nano-scaffolds for Mitigating Chlamydia trachomatis Pathogenesis$2,180,520
U19 · FY2019 · AI
DETERMINANTS OF DIETARY RISK OF HETEROCYCLIC AMINE$2,164,385
P01 · FY2000 · CA
Center for Biologically Inspired Nano-scaffolds for Mitigating Chlamydia trachomatis Pathogenesis$2,052,949
U19 · FY2020 · AI
Center for Biologically Inspired Nano-scaffolds for Mitigating Chlamydia trachomatis Pathogenesis$1,995,618
U19 · FY2021 · AI
Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)$1,966,400
P41 · FY2014 · GM
Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)$1,709,225
P41 · FY2012 · GM
Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)$1,699,208
P41 · FY2010 · RR
Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)$1,682,216
P41 · FY2011 · RR
Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)$1,666,181
P41 · FY2009 · RR
Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)$1,654,246
P41 · FY2013 · GM
Resource for Development of Biomedical Mass Spectrometry$1,552,790
P41 · FY2008 · RR
Resource for Development of Biomedical Mass Spectrometry$1,546,209
P41 · FY2005 · RR
Resource for Development of Biomedical Mass Spectrometry$1,502,278
P41 · FY2007 · RR
Resource for Development of Biomedical Mass Spectrometry$1,469,121
P41 · FY2006 · RR